Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · October 06, 2015

Small Bowel Obstruction Secondary to a Solitary Jejunal RCC Metastasis

Written by
George Yaghmour MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

George Yaghmour MD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Andrew Fintel

    Oct 13, 2015

    Interesting case with a very unusual place for a recurrence of RCC. In this patient who had gone 19 years from removal of his RCC to recurrence, he was then treated with a metastatectomy with no other evidence of disease. You could assume that his tumor biology is less aggressive given the long TTR and for this reason plan for no systemic therapy extrapolating data from the ASSURE trial which tells us that there is no role for Sunitinib or Sorafenib as Adjuvant therapy. On the other hand there are some retrospective trials showing improved PFS when giving TKIs post metastatectomy. 
For this patient I would consider holding off on giving systemic therapy as he had such a long time to relapse and knowing that TKIs do have real side effects, and then reserve using your TKI for another relapse which may not occur for a while. 
To answer the second question, I do not think doing an EGD would be a cost effective screening strategy even in this patient with an odd place for a recurrence. I think regular follow up modalities for metastatic disease would do and leaving endoscopy for symptoms of GI involvement.

  • George Yaghmour

    Oct 26, 2015

    Thanks for your inputs. I think it is reasonable to watch and wait as far the patient underlying cancer biology is not that aggressive. I agree that standard of care follow up surveillance is appropriate and would consider endoscopy for symptoms as needed.

  • Apr 18, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated